Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1994 Apr;32(4):1027–1030. doi: 10.1128/jcm.32.4.1027-1030.1994

Accuracy and cost of antibiotic susceptibility testing of mixed morphotypes of Pseudomonas aeruginosa.

G L Morlin 1, D L Hedges 1, A L Smith 1, J L Burns 1
PMCID: PMC267174  PMID: 8027305

Abstract

Chronic Pseudomonas aeruginosa colonization of the lower respiratory tract of patients with cystic fibrosis frequently results in pulmonary exacerbations requiring treatment with antimicrobial agents. Multiple morphotypes with different antibiotic susceptibilities are often isolated from a single sputum sample. Determination of MICs of antibiotics for each sputum morphotype is used to guide therapy but is time-consuming and expensive. We explored an alternative assay for determining MICs for all P. aeruginosa morphotypes cultured from a homogenized sputum sample. We sought correlations of those MICs with the MIC for the most resistant morphotypes tested separately. The MICs determined for a mixture of morphotypes correctly predicted the highest MICs (+/- one dilution) determined for isolated morphotypes 73.5% of the time. The MIC for the mixed morphotypes correctly predicted susceptibility in 90.4% of samples. In contrast, determination of the MIC for the mixture of morphotypes correctly predicted resistance in only 57.0%. For sputa containing susceptible isolates, testing the mixed culture may provide adequate susceptibility data with significant laboratory time and cost savings. However, for sputa with resistant strains, the traditional method of testing isolated morphotypes should still be used.

Full text

PDF
1027

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abman S. H., Ogle J. W., Harbeck R. J., Butler-Simon N., Hammond K. B., Accurso F. J. Early bacteriologic, immunologic, and clinical courses of young infants with cystic fibrosis identified by neonatal screening. J Pediatr. 1991 Aug;119(2):211–217. doi: 10.1016/s0022-3476(05)80729-2. [DOI] [PubMed] [Google Scholar]
  2. Dunne W. M., Jr, Chusid M. J. Mixed morphotype susceptibility testing of Pseudomonas aeruginosa from patients with cystic fibrosis. Diagn Microbiol Infect Dis. 1987 Feb;6(2):165–170. doi: 10.1016/0732-8893(87)90102-7. [DOI] [PubMed] [Google Scholar]
  3. Gilligan P. H. Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev. 1991 Jan;4(1):35–51. doi: 10.1128/cmr.4.1.35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Maybury B. A., Blessing-Moore J., deWit S. A., Lewiston N. J., Yeager A. S. Antimicrobial susceptibilities of rough, smooth, and mucoid colony types of Pseudomonas isolated from cystic fibrosis patients. Antimicrob Agents Chemother. 1979 Mar;15(3):494–496. doi: 10.1128/aac.15.3.494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Van Horn K. G. Mixed-morphotype broth microdilution susceptibility testing of Pseudomonas aeruginosa from cystic fibrosis patients. J Clin Microbiol. 1993 Feb;31(2):458–459. doi: 10.1128/jcm.31.2.458-459.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Welch D. F., Muszynski M. J., Pai C. H., Marcon M. J., Hribar M. M., Gilligan P. H., Matsen J. M., Ahlin P. A., Hilman B. C., Chartrand S. A. Selective and differential medium for recovery of Pseudomonas cepacia from the respiratory tracts of patients with cystic fibrosis. J Clin Microbiol. 1987 Sep;25(9):1730–1734. doi: 10.1128/jcm.25.9.1730-1734.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Wong K., Roberts M. C., Owens L., Fife M., Smith A. L. Selective media for the quantitation of bacteria in cystic fibrosis sputum. J Med Microbiol. 1984 Apr;17(2):113–119. doi: 10.1099/00222615-17-2-113. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES